Immediate Impact
24 from Science/Nature 78 standout
Citing Papers
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
Targeting HER2-positive breast cancer: advances and future directions
2022 Standout
Works of Raul Ayala being referenced
Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer
2019
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
2003
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Raul Ayala | 476 | 248 | 352 | 17 | 816 | |
| Lisa Malburg | 488 | 179 | 405 | 14 | 770 | |
| Smruthi Vijayaraghavan | 405 | 331 | 545 | 14 | 862 | |
| Emmy D.G. Fleuren | 487 | 301 | 362 | 25 | 853 | |
| Christopher H. Chay | 329 | 183 | 309 | 24 | 723 | |
| Rosalin Mishra | 404 | 136 | 334 | 19 | 698 | |
| Karen A. Reeves | 434 | 166 | 316 | 11 | 751 | |
| Jean Powers | 415 | 262 | 325 | 12 | 741 | |
| Loredana Militello | 353 | 192 | 312 | 18 | 735 | |
| Nishan Tchekmedyian | 293 | 391 | 509 | 17 | 780 | |
| Michel Maira | 622 | 179 | 266 | 12 | 824 |
All Works
Login with ORCID to disown or claim papers
Loading papers...